PACTR201305000552290已完成未知
MONITORING THE EFFICACY AND THE SAFETY OF THREE ARTEMISININ COMBINATIONS THERAPIES (ACT) IN SENEGAL: RESULTS FROM TWO YEARS SURVEILLANCE
niversity Cheikh Anta DIOP of Dakar0 个研究点目标入组 450 人开始时间: 2013年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Year(s) 至 65 Year(s)（—）
- 性别
- All
入选标准
- •Subjects aged over 6 months with the uncomplicated P. falciparum malaria,
- •Parasite density between 1000 and 100000 trophozoites/¿l,
- •Presence of an axillary temperature higher than 37.5° or history of fever during the previous 24 hours,
- •Ability to take oral medication and given her inform consent were included in the study
排除标准
- •Patients presenting mono-infestation by another species or mixted infestation, severe vomiting, severe malnutrition, severe signs of malaria (such as severe anemia, convulsion, respiratory distress), women with positive pregnancy test and patients who had a history of allergy to study drugs or not given her inform consent were excluded in the study
研究者
相似试验
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-CZGalderma Research & Development SNC270
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSEUCTR2006-001999-20-HUGalderma Research & Development SNC270
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-DEGalderma Research & Development SNC274
尚未招募
不适用
COMPARING SAFETY AND EFFICACY OF 3 DIFFERENT DOSES OF FENTANYL TO HEMODYNAMIC STRESS RESPONSE TO LARYNGOSCOPY AND INTUBATIOCTRI/2021/07/035113DEPARTMENT OF ANESTHESIOLOGY
进行中（未招募）
3 期
study to access effectiveness of new drug therapy (aspirin,atorvastatin and nicorandil) in covid-19CTRI/2021/04/032648Dr Ambudhar Sharma